How to access Dupixent for atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis, or COPD with eosinophilic phenotype from Saudi Arabia: 2026 pathway via SFDA-coordinated registration, the MOH specialty network, and named-patient import where required | Reserve Meds
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Saudi Arabia operates the largest multi-specialty dermatology, pulmonology, allergy, ENT, gastroenterology, and paediatrics network in the GCC. King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh and Jeddah anchor the academic medical centre layer with deep paediatric and adult subspecialty coverage. King Saud Medical City Riyadh, King Abdulaziz Medical City (NGHA), Prince Sultan Military Medical City, King Khalid University Hospital, King Fahad Specialist Hospital Dammam, the Dr Sulaiman Al Habib network across major cities, the Saudi German Hospital network, Dr Soliman Fakeeh Hospital Jeddah, and the Mouwasat Hospital network round out the prescribing landscape. All run programmes treating moderate-to-severe atopic dermatitis in adults and children, severe eosinophilic and oral-corticosteroid-dependent asthma in adults and children, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease with an eosinophilic phenotype. Dupixent (dupilumab, Regeneron and Sanofi) is the fully human IgG4 monoclonal antibody that blocks IL-4Ra and thereby suppresses both IL-4 and IL-13 type 2 cytokine signalling. SFDA registration is in place for the adult atopic dermatitis and adult asthma indications since 2018; the CRSwNP, EoE, prurigo nodularis, paediatric subsets across age brackets, and COPD indications carry registration that has evolved across multiple expansions. For a Saudi-resident patient whose disease has plateaued on conventional therapy or who has failed a prior biologic, the operational question is no longer whether IL-4 and IL-13 receptor blockade is reachable in the country: it is whether Dupixent is the right fit for the patient's specific indication, how the prescription is dispensed in 2026, what insurance will cover, what pre-treatment screening looks like, and how the family handles the every-2-week (or every-4-week, or weekly for EoE) subcutaneous routine.
This page explains how the pathway works in 2026 for a Saudi-resident patient. Atopic dermatitis is the most common entry point into Dupixent therapy across the GCC, so the page leads with the atopic dermatitis pathway. A dedicated section covers the other five approved indications (asthma, CRSwNP, EoE, prurigo nodularis, COPD) with eligibility per indication. It is concierge documentation written for a family already in conversation with a treating specialist who wants the operational reality laid out plainly.
Why Dupixent, and why now
Dupixent is dupilumab, a fully human IgG4 monoclonal antibody developed jointly by Regeneron and Sanofi. The molecule binds the alpha subunit of the interleukin-4 receptor (IL-4Ra), the shared subunit of the type I and type II IL-4 receptors. By binding IL-4Ra, dupilumab blocks the downstream signalling of both IL-4 and IL-13, the two central cytokines of type 2 inflammation. Type 2 inflammation is the unifying mechanism across atopic dermatitis, eosinophilic asthma, CRSwNP, EoE, prurigo nodularis, and the eosinophilic phenotype of COPD. Blocking the IL-4 and IL-13 signal reduces eosinophil recruitment to tissues, dampens IgE production by B cells, restores epithelial barrier function in skin and esophagus, reduces mucus production in airway epithelium, and breaks the chronic itch and inflammation cycle.
FDA approval timeline: adult moderate-to-severe atopic dermatitis March 2017; adult and adolescent (12+) asthma October 2018; adolescent atopic dermatitis March 2019; CRSwNP June 2019; paediatric atopic dermatitis (6 to 11 years) May 2020; paediatric asthma (6 to 11 years) October 2021; atopic dermatitis (6 months to 5 years) June 2022; EoE adult and adolescent (12+) May 2022; prurigo nodularis September 2022; EoE paediatric (1 to 11 years, at least 15 kg) January 2024; COPD with eosinophilic phenotype September 2024; paediatric asthma (6 months to 5 years) April 2025. This breadth across indication and age is unmatched in the type 2 inflammation biologic class and is the reason Dupixent often shows up as the first specialist-prescribed biologic for a Saudi patient with overlapping atopic conditions (the atopic march).
Reserve Meds does not promote one biologic over another. The competing type 2 inflammation biologic landscape in 2026 includes omalizumab (Xolair, anti-IgE), mepolizumab (Nucala, anti-IL-5), reslizumab (Cinqair, anti-IL-5), benralizumab (Fasenra, anti-IL-5Ra), tezepelumab (Tezspire, anti-TSLP), tralokinumab (Adbry, anti-IL-13 for adult AD), and lebrikizumab (Ebglyss, anti-IL-13 for adult AD). The JAK inhibitor class (abrocitinib Cibinqo, upadacitinib Rinvoq) is an alternative for moderate-to-severe atopic dermatitis with a small-molecule oral mechanism and a class black-box warning. Choice across these alternatives is the central clinical decision and varies by indication, phenotype, comorbidities, and patient preference.
What Dupixent is, in plain language
Dupixent is a subcutaneous injection given every 2 weeks for most adult indications, every 4 weeks for the lighter-weight paediatric atopic dermatitis subsets, and weekly for EoE. It is not an infusion. After an initial training session at the prescribing physician's clinic or with a Sanofi nurse educator, most adult patients self-administer at home using the pre-filled pen (auto-injector) or pre-filled syringe at 300 mg, 200 mg, or 100 mg per device. Caregivers administer for paediatric patients. Cold-chain storage at 2 to 8 degrees Celsius is required.
Adult atopic dermatitis dose: 600 mg load (two 300 mg injections at separate sites at the same visit), then 300 mg every 2 weeks. Adult asthma dose: 400 mg load then 200 mg every 2 weeks, with the 600 mg load and 300 mg every 2 weeks schedule for OCS-dependent asthma or asthma with comorbid moderate-to-severe atopic dermatitis. CRSwNP: 300 mg every 2 weeks. EoE: 300 mg once weekly (distinct cadence). Prurigo nodularis: 600 mg load then 300 mg every 2 weeks. COPD with eosinophilic phenotype: 300 mg every 2 weeks. Paediatric atopic dermatitis dosing is weight-tiered (200 mg q4w for 5 to less than 15 kg; 300 mg q4w for 15 to less than 30 kg; 400 mg load then 200 mg q2w for 30 to less than 60 kg; adult regimen for 60 kg and above). Paediatric asthma and paediatric EoE follow similar weight-tiered tables.
This is not a one-shot or short-course therapy. Dupixent is taken for as long as it controls the disease. Patients who respond typically stay on Dupixent for years.
Eligibility at a Saudi specialist clinic
For Saudi-resident patients, the prescribing specialties apply FDA and EMA criteria with local insurance and MOH adaptation. Eligibility is indication-specific:
1. Atopic dermatitis: dermatologist or paediatric dermatologist confirms moderate-to-severe disease by IGA, EASI, BSA, and DLQI (or POEM in younger patients). Documented inadequate response to topical prescription therapies. Age 6 months or older. 2. Asthma: pulmonologist or allergist confirms moderate-to-severe asthma by GINA Step 4 or 5. Eosinophilic phenotype confirmed by blood eosinophil count or FeNO; or OCS-dependent asthma. Age 6 years or older (6 months and older per the 2025 paediatric expansion). 3. CRSwNP: ENT confirms bilateral nasal polyposis with documented inadequate response to intranasal corticosteroids and either systemic corticosteroid courses or sino-nasal surgery. Adult only. 4. EoE: gastroenterologist or paediatric gastroenterologist confirms by endoscopy with biopsy at least 15 eosinophils per HPF after a PPI trial. Age 1 year and older, weight at least 15 kg. 5. Prurigo nodularis: dermatologist confirms multiple intensely pruritic nodules, chronic course at least 6 weeks, alternative causes excluded. Adult only. 6. COPD with eosinophilic phenotype: pulmonologist confirms COPD by post-bronchodilator spirometry, blood eosinophils at least 300 cells per microlitre, inadequately controlled on optimised triple inhaled therapy. Adult only.
Shared baseline elements across all indications:
7. Treatment history. Failure of (or contraindication to) appropriate prior therapy. Documented prior failures are common pre-authorisation requirements. 8. Baseline laboratory panel. CBC with eosinophil count, comprehensive metabolic panel, total IgE (informative not gating), pregnancy test for women of reproductive potential. 9. Helminth infection screen for patients with epidemiologic risk. Treat any pre-existing helminth before initiation. 10. Active serious infection is a reason to defer. 11. Vaccination status review. Live vaccines not recommended during therapy. Catch-up before initiation where feasible. Inactivated vaccines permitted and recommended. 12. Conjunctivitis history review for atopic dermatitis patients. 13. Pregnancy and lactation discussion for women of reproductive potential.
A Saudi patient should arrive at the biologic conversation with the most recent specialist documentation for the indication, complete treatment history, prior biologic trial documentation if any, baseline screening labs, helminth screen where indicated, vaccination record, and the insurance pre-authorisation paperwork.
The Saudi prescribing and supply picture, plainly
SFDA (Saudi Food and Drug Authority) registration status for Dupixent is in place for adult atopic dermatitis and adult asthma since 2018, with newer indications and age subsets at various registration stages. NUPCO handles MOH and military hospital procurement supply chain at scale. Where in-country registration is complete for an indication and age subset, local commercial pharmacy supply applies. Where registration has not caught up with the latest FDA or EMA label, a named-patient European or US import pathway covers the case. The pathway:
1. Prescribing physician: a Saudi board-certified specialist in the indication-appropriate discipline. Dermatology or paediatric dermatology for AD and prurigo. Pulmonology, allergy, or paediatric pulmonology for asthma. Pulmonology for COPD. ENT for CRSwNP. Gastroenterology or paediatric gastroenterology for EoE. Prescribing centres: KFSHRC Riyadh and Jeddah, King Saud Medical City Riyadh, KAMC NGHA, Prince Sultan Military Medical City, King Khalid University Hospital, King Fahad Specialist Hospital Dammam, Dr Sulaiman Al Habib network, Saudi German Hospital network, Dr Soliman Fakeeh Hospital, Mouwasat Hospital network. 2. Pharmacy dispensing: hospital outpatient pharmacy or licensed community pharmacy with cold-chain handling. Dupixent requires 2 to 8 degree Celsius transport and storage. NUPCO-supplied MOH and military pharmacies dispense via the national supply chain; private hospital and community pharmacies dispense via commercial supply. 3. Insurance pre-authorisation: MOH coverage for Saudi nationals routes through the MOH facility network with pre-authorisation handled internally; CCHI (Council of Cooperative Health Insurance) governs commercial insurance for residents through Bupa Arabia, Tawuniya, MedGulf, AXA Cooperative, Allianz SF, and others. All process Dupixent pre-authorisation routinely for adult AD and adult asthma. CRSwNP, EoE, prurigo, paediatric subsets, and COPD pre-authorisation patterns vary by payer and by recency. Documented severity, prior-therapy failure, and specialist sign-off are the common requirements. 4. Self-injection training: single supervised session at the prescribing physician's clinic or via a Sanofi nurse educator visit. Most adult patients are comfortable after 1 to 2 sessions. Caregivers train for paediatric patients. 5. Ongoing monitoring: specialty-specific follow-up at week 4, 12, and 16, then quarterly through year one. Conjunctivitis surveillance at every visit for AD patients. Eosinophil count at baseline and periodically.
The 2026 pathway, step by step
Week 0 to 1: Reserve Meds builds the documentation pack with the treating specialist's office. We collect current severity scores, photographs of involved skin if applicable, endoscopy and biopsy reports if applicable, spirometry and eosinophil data if applicable, complete treatment history, prior biologic trial documentation if any, baseline screening labs, helminth screen where indicated, vaccination record, and insurance card details. The prescribing office submits insurance pre-authorisation.
Week 1 to 4: Insurance pre-authorisation review. CCHI commercial insurers typically turn this around within 2 to 4 weeks for adult AD and adult asthma; CRSwNP, EoE, prurigo, paediatric subsets, and COPD may take longer. MOH pre-authorisation runs in parallel for nationals.
Week 4 to 6: First dispensing. Indication-specific loading dose plus self-injection training. Patient takes home the next dose for the next scheduled injection.
Week 4 onwards: Patient self-injects at home per the indication-specific schedule. Reserve Meds coordinates cold-chain delivery of the next month's supply.
Week 4 to 16: Loading-phase completion and early-response assessment. Specialty follow-up visits at week 4, 12, and 16.
Week 16 onwards: Response assessment. Maintenance dosing for responders. Inadequate responders may extend response assessment window or switch therapy under specialist supervision.
Ongoing: Maintenance dosing for as long as Dupixent controls the disease. Quarterly follow-up at minimum during the first year; less frequent for stable responders thereafter.
Cost band and insurance positioning
US WAC list price for Dupixent 300 mg is approximately USD 3,800 to 4,300 per pre-filled pen or syringe. For the every-2-week adult regimen, annual cost at list is approximately USD 91,000 to 103,000. The weekly EoE regimen carries a substantially higher annual list price (approximately USD 200,000 plus). The weight-tiered paediatric q4w regimens land lower (approximately USD 45,000 to 55,000 annual at list).
At 2026 indicative cross rates, the SAR-equivalent annual cost band for the every-2-week adult 300 mg regimen is approximately SAR 340,000 to 390,000 at list price. Paediatric q4w regimens land lower (approximately SAR 170,000 to 205,000 at list). The weekly EoE regimen lands materially higher. Pre-authorisation reduces out-of-pocket exposure substantially. MOH coverage for Saudi nationals at MOH facilities applies to the registered indications within the standard pre-authorisation framework. CCHI-governed commercial covers include Dupixent for the registered indications.
For Saudi nationals, the financial pre-authorisation conversation needs to start before the first dispensing. For expatriate residents on CCHI-governed commercial insurance, the same applies; the prescribing physician's office is the gating step.
What to expect on Dupixent, by indication
Atopic dermatitis: itch reduction often within 2 to 4 weeks. EASI-75 in approximately 50 percent and IGA 0 or 1 in approximately 38 percent at week 16 in monotherapy pivotal trials; higher in combination with topical corticosteroids (approximately 65 percent EASI-75 at week 52 in CHRONOS). Sleep and DLQI improvement parallel.
Asthma: approximately 47 percent (200 mg arm) and 46 percent (300 mg arm) reduction in annualised severe exacerbation rate in QUEST. FEV1 improvement approximately 0.32 L. Benefit concentrated in eosinophilic phenotype subgroup. OCS-dependent patients (VENTURE): median 70 percent OCS dose reduction; 48 percent achieve complete OCS discontinuation by week 24.
CRSwNP: nasal polyp score reduction by approximately 2 points at week 24. Time to first sino-nasal surgery extended.
EoE: histologic remission at week 24 in approximately 60 percent on weekly dupilumab versus 5 percent on placebo. DSQ improvement approximately 12 points versus 6.
Prurigo nodularis: at least 4-point Worst Itch NRS reduction at week 24 in approximately 60 percent versus 18 percent on placebo.
COPD with eosinophilic phenotype: approximately 30 percent and 34 percent annualised reduction in moderate or severe exacerbations in BOREAS and NOTUS respectively.
The first 4 to 16 weeks are the highest-vigilance window. Patients not responding by week 16 (or week 24 for slower-responding indications) are reassessed.
Other approved indications, eligibility summary
- Asthma (adult and paediatric 6 months and older): moderate-to-severe with eosinophilic phenotype or OCS dependence. Pulmonology or allergy prescribing. - CRSwNP (adult): bilateral nasal polyposis, inadequate response to INCS and either OCS courses or surgery. ENT prescribing. - EoE (adult and paediatric 1 year and older, at least 15 kg): endoscopy-and-biopsy at least 15 eos per HPF after PPI trial. Weekly dosing. GI prescribing. - Prurigo nodularis (adult): multiple intensely pruritic nodules, chronic course at least 6 weeks. Dermatology prescribing. - COPD with eosinophilic phenotype (adult): COPD by post-bronchodilator spirometry, blood eosinophils at least 300, inadequate control on optimised triple inhaled therapy. Pulmonology prescribing.
For patients with multiple comorbid type 2 inflammation conditions, Dupixent may treat multiple comorbid conditions simultaneously. This is worth surfacing in the eligibility conversation.
What to monitor
The most clinically distinctive Dupixent monitoring item is conjunctivitis, especially for atopic dermatitis patients (approximately 10 to 20 percent incidence on therapy). Bilateral red eye, itch, tearing, occasional photophobia. Most cases respond to lubricants, lid hygiene, topical corticosteroid drops under ophthalmology supervision. Ophthalmology referral at first sign that does not resolve within 48 hours.
Eosinophil count at baseline and periodically. Transient eosinophilia common; usually returns to baseline within 6 to 12 months. Sustained eosinophilia with new respiratory or systemic features prompts evaluation for eosinophilic pneumonia or EGPA (rare).
Injection-site reactions, oral herpes (HSV reactivation), and other common AEs usually managed without therapy interruption.
Helminth surveillance for patients with epidemiologic exposure.
Hypersensitivity including rare anaphylaxis: stop therapy if it occurs.
Live vaccines avoided during therapy.
Long-term safety: 7-plus years post-marketing, reassuring profile, no opportunistic infection signal, no malignancy signal, no class black-box warning.
Religious, ethical, and family-logistics framing
Dupixent is a fully human IgG4 monoclonal antibody produced in CHO cell culture. There is no donor element, no human or animal source material in the active ingredient, and no foreign genetic content delivered to the patient. The classical analogy to vaccines and other recombinant biologics holds in Saudi Islamic medical ethics, where biologics produced in this manner are generally treated as permissive with the standard expectation that the family decides in consultation with the treating physician. Excipient sourcing varies; patients with specific halal-certification requirements should ask the dispensing pharmacy.
The self-injection element is the practical pressure point for some Saudi families. Patients uncomfortable with home injection can request clinic-administered dispensing. Most patients are comfortable with self-injection after the initial training; the pen is straightforward. For paediatric patients, caregivers train; the transition to self-administration in adolescence is a milestone conversation.
The cold-chain storage requirement is operationally important in the Saudi summer climate. Patient counselling on home refrigerator placement, travel handling (insulated cold-chain bag with cold pack), and the 14-day room-temperature allowance in the original unopened carton is part of standard patient education.
Severe AD in a child, severe asthma in a child, EoE in a child, and CRSwNP in an adult all carry meaningful family-burden and quality-of-life dimensions. Sleep disturbance, school absenteeism, work absenteeism, feeding difficulty, body-image concerns, and depression burden in patients and parents are real. The clinical conversation appropriately addresses these dimensions and includes behavioural health referral where indicated. Dupilumab itself has no CNS or mood signal; the psychosocial burden is from the underlying chronic disease, and treatment response generally improves these dimensions in parallel.
Ramadan considerations: the every-2-week or every-4-week subcutaneous regimen is unaffected by Ramadan fasting. EoE patients on the weekly regimen plan injection timing around the meal schedule. Asthma exacerbation risk during Ramadan deserves explicit conversation for OCS-dependent and severe eosinophilic asthma patients.
Hajj and Umrah travel planning: meningococcal conjugate vaccination (inactivated) is permitted and recommended for travellers. Cold-chain travel planning for the injection during travel is straightforward with an insulated cold-chain bag.
Vaccination during therapy: live vaccines (varicella, MMR, yellow fever, oral polio, BCG) not recommended. Inactivated vaccines (annual influenza, pneumococcal, COVID-19, meningococcal conjugate) permitted and recommended.
When Dupixent is the wrong drug
For a Saudi patient with the following clinical profiles, the operational pathway shifts:
- Acute asthma exacerbation, status asthmaticus, acute bronchospasm: Dupixent has no role in acute care. Standard rescue therapy applies. - Asthma without eosinophilic phenotype and without OCS dependence: tezepelumab (Tezspire) is positioned across asthma phenotypes for patients who do not fit the eosinophilic profile. - CRSwNP responding adequately to INCS alone: Dupixent is for inadequate response. - EoE responding adequately to PPI or dietary elimination: Dupixent is for inadequate response. - COPD without eosinophilic phenotype: non-eosinophilic COPD does not benefit. - Active helminth infection: treat before initiation. - Hypersensitivity to dupilumab or excipients: contraindicated. - Active serious infection: defer initiation. - Need for live vaccination in the near term: complete the live vaccination then initiate Dupixent. - Severe conjunctivitis history with poor ophthalmology support: not a contraindication but warrants an ophthalmology co-management plan. - Pregnancy: not contraindicated per se but limited human data; individualised decision.
Alternative type 2 inflammation biologics in 2026: omalizumab, mepolizumab, reslizumab, benralizumab, tezepelumab, tralokinumab, lebrikizumab, nemolizumab. JAK inhibitor alternatives for adult AD: abrocitinib, upadacitinib.
Reserve Meds does not promote one biologic over another. If the conversation with the treating specialist points toward a different biologic, a JAK inhibitor, or continued conventional therapy, the operational pathway shifts accordingly.
What Reserve Meds does on this case
We are a US-based concierge coordinator. We are not the prescriber and not the dispensing pharmacy. On a Saudi Dupixent case we build the documentation pack with the treating specialist office, confirm SFDA registration status per indication and per age subset and the appropriate dispensing pathway (MOH-coordinated for nationals where applicable, CCHI commercial for residents, named-patient European or US import for off-formulary cases), run the insurance pre-authorisation conversation alongside the clinical conversation, coordinate the cold-chain supply logistics for ongoing maintenance dispensing, organise self-injection training and the baseline screening the prescribing office requires, set up the ophthalmology co-management plan for atopic dermatitis patients where indicated, and stay with the case through the first year of dosing with handoff to the local prescriber for ongoing surveillance. Clinical decisions remain with your treating specialist.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating specialist.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.